Global Alzheimer's Disease Therapeutics and Diagnostics Market 2018-2028 - Visiongain Report

Monday, July 2, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 2, 2018 /PRNewswire/ --

Leading Drugs, R&D Pipeline Drugs, Biomarkers,

Leading Companies

The Alzheimer's Disease Therapeutics and Diagnostics Market will reach $7.93bn in 2018. The Alzheimer's Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 12.1% in the

second half of the forecast period.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 208-page report you will receive 62 tables and 82 figures- all unavailable elsewhere.

The 208-page report provides clear detailed insight into the Alzheimer's Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Alzheimer's Disease Market forecasts from 2018-2028, further broken down into: • Alzheimer's Drugs Market • Alzheimer's Diagnostics Market

• Quantitative analysis of the Alzheimer's drug market from 2018 to 2028. It includes analysis and forecast of top drugs and pipeline drugs in the market: • Namenda • Aricept • Exelon • Solanezumab • Gantenerumab • Verubecestat

• Quantitative analysis of the Alzheimer's diagnostics market from 2018-2028. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer's diagnosis from 2018 to 2028: • Diagnostic biomarker market • Others

• Profiles of leading pharma companies involved in developing Alzheimer's drugs globally. It contains overviews of the companies' segments, recent mergers and acquisitions and analysis of the companies' recent financial performances. It also includes the details of the drugs for Alzheimer's in the pipeline and forecast of the company drugs available in the market: • Pfizer • Eisai • Actavis • Lundbeck • Daiichi Sankyo • Novartis • TauRx • vTv Therapeutics

• Profiles of leading companies developing diagnostics tests for Alzheimer's disease: • Eli Lilly • Amarantus Biosciences Holdings • Piramal Enterprises • GE Healthcare • Navidea • DiaGenic

• This report also breaks down the revenue forecast for the Alzheimer's Disease Market by national market: • US Germany France Italy Spain • UK Japan China Brazil India Russia

• This report covers the qualitative analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.

• This report shows transcripts of research interviews conducted by visiongain: • David Hung, Chief Executive Officer of Axovant Sciences Inc. • Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare • Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.

Buy our report today Global Alzheimer's Disease Therapeutics and Diagnostics Market 2018-2028: Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/report/global-alzheimers-disease-therapeutics-and-diagnostics-market-2018-2028

AbbVie AB Science  AC Immune Acadia Pharmaceuticals Accera Actavis Adamas Pharmceuticals  Affiris  Allergan Amarantus BioSciences Amorphis Amgen Archer Pharmaceuticals Astellas Pharma Astex AstraZeneca Avanir Pharmaceuticals  Avineuro Pharmaceuticals Axovant Sciences Inc AZ Therapies Inc Baxter Bayer Bayer Schering Pharma  Biogen  bioMerieux  Boehringer Ingelheim Bristol Myers Suibb Ceregene Chiesi Farmaceutici Cognoptix  Cytos  Daiichi Sankyo DiaGenic  Eisai Elan Eli Lilly EnVivo Pharmaceuticals European Medicines Agency (EMA) Forest Laboratories Forum Pharmaceuticals Foundation Medical Partners Functional Neuromodulation  Food and Drug Administration (FDA) GE Healthcare  General Electric  Genervon Biopharmaceuticals Genesys Capital GSK  Hisamitsu Pharmaceutical Humanetics IBA Molecular  J&J Janssen Alzheimer Immunotherapy Research & Development Janssen Pharmaceutical K. K  Kareus Therapeutics  LabCorp Luminex  Lundbeck Medtronic Merck & Co Merz Meso Scale Diagnostics  Metabolic Solutions Development Company MorphoSys Nanotherapeutics National Institute of Health (NIH) National Institute for Health and Care Excellence (NICE)  Navidea NextGen Sciences  Novartis Novo Nordisk  Ono Pharmaceutical  OPKO Ortho Clinical Diagnostics  Otsuka Pharmaceutical  Oxford BioDynamics  Par Pharmaceuticals  Pfizer Piramal Enterprises  Piramal Imaging  Proteome Sciences  ProteoTech Proterra QR Pharma Quanterix  Raptor Pharmaceutical  Resverlogix  Roche Roche Diagnostics  Saladax  Sandoz Sangamo BioSciences Sanofi sGC Pharma Shionogi Shire Siemens Medical Solutions USA  Somalogic  Sonexa Therapeutics Sun Pharma T3D Therapeutics Takeda Targacept TauRx  Toyama Chemical Transition Therapeutics TransTech Pharma United Biomedical VIVUS Wyeth

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store